Turn Therapeutics Schedules Webcast on Interim Analysis and Optimized Stage 2 Design for GX-03
TTRX•Turn Therapeutics will host a webcast presenting comprehensive interim analysis and optimized Stage 2 design for its GX-03 atopic dermatitis candidate. The live event will outline protocol refinements aimed at streamlining patient enrollment and sharpening clinical endpoints for the upcoming trial phase.
1. Webcast Announcement
Turn Therapeutics will host a webcast to present a comprehensive interim analysis and the optimized Stage 2 design for its GX-03 atopic dermatitis program, targeting researchers and investors interested in clinical development milestones.
2. Stage 2 Design Optimization
The updated Stage 2 trial design will leverage insights from the interim analysis to refine patient inclusion criteria, adjust dosing strategy and sharpen endpoint definitions, positioning the program for efficient progression to the next development stage.
